Transaction To Evaluate BioNumerik’s Tavocept Announced By Lantern Pharma

Lantern Pharma Announces Transaction to Evaluate BioNumerik’s Tavocept.Lantern Pharma, Inc.and BioNumerik Pharmaceuticals, Inc. of San Antonio, Texas have entered into an exclusive agreement for Lantern Pharma to evaluate BioNumerik’s Tavocept® for human therapeutic indications using Lantern’s 5-M theranostic platform.

Source:
www.businesswire.com/news/home/20160805005811/en/Lantern-Pharma-Announces-Transaction-Evaluate-BioNumerik%E2%80%99s-Tavocept%C2%AE